Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP

Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy...

Full description

Bibliographic Details
Main Authors: Martin Faehling, Christian Schumann, Petros Christopoulos, Petra Hoffknecht, Jürgen Alt, Marlitt Horn, Stephan Eisenmann, Anke Schlenska-Lange, Philipp Schütt, Felix Steger, Wolfgang M. Brückl, Daniel C. Christoph
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Data in Brief
Subjects:
NSCLC
PD-L1
Checkpoint inhibitor
Survival
Real world
Oligometastatic
Online Access:http://www.sciencedirect.com/science/article/pii/S2352340920314384

Similar Items

Similar Items